Short-Term Oral Sorafenib for Therapy of Intratumoral Shunts of Hepatocellular Carcinoma to Enable Intraarterial Treatment

INTRODUCTION: Significant intratumoral shunts between tumor-supplying arteries and portal or liver veins are a contraindication for transarterial therapy of HCC because interventional treatment of these shunts is frequently insufficient. Sorafenib has anti-angiogenic effects and is indicated for pal...

Descripción completa

Detalles Bibliográficos
Autores principales: Thüring, J., Zimmermann, M., Bruners, P., Pedersoli, F., Schulze-Hagen, M., Barzakova, E., Kuhl, C. K., Isfort, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Technical Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715807/
https://www.ncbi.nlm.nih.gov/pubmed/31363899
http://dx.doi.org/10.1007/s00270-019-02294-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715807/
https://www.ncbi.nlm.nih.gov/pubmed/31363899
http://dx.doi.org/10.1007/s00270-019-02294-7

Ejemplares similares